BiVictriX Therapeutics PLC BiVictriX: Board Change (8691L)

TIDMBVX

RNS Number : 8691L

BiVictriX Therapeutics PLC

06 January 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company" or the "Group")

Board Change

Dr. Michael Kauffman, M.D., Ph.D. appointed as Non-Executive Chairman

Iain Ross to remain a Board member

Alderley Park, 6 January 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces that Dr. Michael Kauffman, M.D., Ph.D. has been appointed as Non-Executive Chairman. Dr Kauffman takes over from Iain Ross, who will continue as a Non-Executive Director on the BiVictriX Board, but steps down as Chairman due to other work commitments.

Prior to becoming Non-Executive Chairman, Dr. Kauffman was appointed as Non-Executive Director of BiVictriX in January 2022. He is a highly experienced cancer drug developer, having been instrumental in the approval of several oncology therapeutics over twenty years of working across preclinical research, clinical development, regulatory strategy and commercialisation. As Non-Executive Chairman, he will draw upon his previous experience as Co-Founder and Chief Executive Officer of oncology company Karyopharm Therapeutics Inc., which he guided from a discovery stage biotechnology company to a commercial stage organisation, with global approvals of XPOVIO(R). He also led the Kyprolis(R) development programme at Proteolix and then Onyx Pharmaceuticals, the Velcade(R) development programme at Millennium Pharmaceuticals, and has held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr Kauffman currently holds other Non-Executive Board positions at Verastem Oncology, Adicet Bio and Kezar Life Sciences.

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, commented: "With the recent identification of our lead candidate, the transition of Michael Kauffman to Non-Executive Chairman of the Board comes at a pivotal time in BiVictriX's development. I am delighted to welcome Michael to his new role; no doubt his wealth of expertise across oncology drug development will continue to prove invaluable during the next stage of our progression. I would like to also express gratitude on behalf of the whole Company to Iain for his excellent support, taking us through from IPO to candidate identification and look forward to continuing to work alongside him as a valued member of our Board."

Dr. Michael Kauffman , Non-Executive Chairman of BiVictriX , added: "Having been a member of BiVictriX's Board over the past year, I have witnessed the Company's remarkable progress and am excited to step up to Chairman at this stage of the Company's development. The Bi-Cygni(R) platform is designed to optimise the potential of ADCs by reducing off target-binding associated with toxicities and increasing tumor-selective killing. I am looking forward to BiVictriX progressing BVX001 into the clinic, where we hope to be differentiated by our delivery of key outcomes in cancer-selective therapies for the support of patients who currently have limited options."

Iain Ross, Non-Executive Director at BiVictriX, commented: "It has been a privilege to have chaired the BiVictriX Board over the past couple of years and to have seen it grow into such a strong position. I am now, as a result of additional responsibilities at ReNeuron Group plc, handing over the reins to Michael, who is well experienced to support the Company as Chairman as it enters its next stage of pipeline development. I look forward to remaining actively involved in BiVictriX as a Non-Executive Director."

For more information, please contact:

 
 BiVictriX Therapeutics plc 
 Tiffany Thorn, Chief Executive Officer 
  Michael Kauffman, Non-Executive           Email: [e-mail] 
  Chairman 
 
 SP Angel Corporate Finance LLP           Tel: [phone] 
  (NOMAD and Broker) 
 David Hignell, Kasia Brzozowska 
  (Corporate Finance) 
  Vadim Alexandre, Rob Rees (Sales 
  and Broking) 
 
 Panmure Gordon (UK) Limited (Joint       Tel: [phone] 
  Broker) 
 Rupert Dearden, Freddy Crossley, 
  Emma Earl 
 
   Consilium Strategic Communications 
   Mary-Jane Elliott, Namrata Taak,         Tel: [phone] 
   Genevieve Wilson, Alex Gunter            Email: [e-mail] 
 
 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related harmful side effects.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target cancer-specific antigen pairs, or "twin antigens fingerprints", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting, where it offers the opportunity to be a game-changing approach to cancer care.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens fingerprints" across a broad range of cancer indications. The Company is using these novel twin antigens to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOASSLESIEDSEIF

(END) Dow Jones Newswires

January 06, 2023 02:00 ET (07:00 GMT)